Pediatrics hero
Pediatrics hero

Pediatric VTE and post-Fontan care are complex.1,2

Helping protect against thrombosis doesn’t have to be.

FDA APPROVED with 2 indications in pediatric patients3

Pediatric VTE

Pediatric Post Fontan

XARELTO®: the direct oral anticoagulant (DOAC) studied in the largest clinical trials for pediatric VTE treatment and prevention (N=500) and for pediatric patients post-Fontan procedure (N=110)4-8

Pediatric Resources

DOWNLOAD INTERACTIVE PDF

VIEW INSTRUCTIONS FOR USE VIDEO

References: 1. Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292-3316. doi:10.1182/bloodadvances.2018024828 2. Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease. A scientific statement from the American Heart Association. Circulation. 2013;128(24):2622-2703. doi:10.1161/01.cir.0000436140.77832.7a 3. XARELTO® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 4. Male C, Lensing AWA, Palumbo JS, et al; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2019;7(1):e18-e27. 5. ClinicalTrials. gov. NCT01895777. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). Accessed April 29, 2022. 6. ClinicalTrials.gov. NCT02464969. Apixaban for the acute treatment of venous thromboembolism in children. Accessed April 29, 2022. 7. ClinicalTrials.gov. NCT02798471. Hokusai study in pediatric patients with confirmed venous thromboembolism (VTE). Accessed April 29, 2022. 8. McCrindle BW, Michelson AD, Van Bergen AH, et al; UNIVERSE Study Investigators. Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc. 2021;e021765. doi:10.1161/JAHA.120.021765